ResumenEl propósito del presente estudio fue cuantificar la presencia de la quimiocina CCL5 (RANTES) en Líquido Crevicular Gingival (LCG) de pacientes con Periodontitis Crónica (PC) y/o Diabetes Mellitus tipo 2 (DM2). Se realizó un estudio comparativo, transversal en 40 pacientes. Se tomó LCG de bolsas periodontales y surcos gingivales de 4 grupos de pacientes (10 por grupo de estudio), se excluyó a los pacientes que recibieron tratamiento periodontal, antibiótico y antiinflamatorio 6 meses anteriores al estudio o cursaron con alguna enfermedad sistémica distinta a DM2. Las concentraciones de CCL5 se determinaron mediante ensayos LUMINEX de selección magnética. Se realizó estadística descriptiva, prueba ANOVA de una vía, T de student y correlación de Pearson. La cuantificación de CCL5 fue mayor en los pacientes que presentaron ambas enfermedades, seguidos del grupo con solo PC, los sanos y el grupo con solo DM2. No se encontró diferencia significativa entre los grupos y no hubo correlación entre las cuantificaciones y los indicadores glicémicos. A pesar de que las diferencias no fueron significativas, el grupo de pacientes con ambas enfermedades presentó la mayor cuantificación de CCL5. La expresión de CCL5 en LGC debe considerarse un potencial inductor de destrucción periodontal, su determinación podría ser útil para monitoreo de la salud/enfermedad de los tejidos periodontales.

AbstractThe purpose of the present study was to quantify the presence of chemokine CCL5 (RANTES) in gingival crevicular fluid (LCG) in patients with chronic periodontitis (PC) and / or type 2 diabetes mellitus (DM2). A comparative cross-sectional study was conducted in 40 patients. LCG was taken from periodontal pockets and gingival grooves from 4 patient groups (10 per study group); patients who received periodontal, antibiotic and anti-inflammatory treatment 6 months prior to the study or who had systemic disease other than DM2 were excluded. Concentrations of CCL5 were determined by LUMINEX® assays. Descriptive statistics, one-way ANOVA, Student's T, and Pearson's correlation were performed. The quantification of CCL5 was higher in the patients who presented both diseases, followed by the group with only PC, healthy and the group with only DM2. No significant difference was found between groups and there was no correlation between quantifications and glycemic indicators. Although the differences were not significant, the group of patients with both diseases had the highest CCL5 quantification. The expression of CCL5 in LGC should be considered as a potential inducer of periodontal destruction, its determination could be useful for monitoring the health/disease of periodontal tissues.

Abstract C-Reactive Protein (CRP) is one of the plasma proteins that appear in the acute phase of inflammation. Periodontitis is associated with elevated levels of CRP in adults and with its decreasing after treatment. On the other hand, diabetes is a disease that compromises both the inflammatory and reparative response of the body and the periodontal tissues are particularly sensitive to its effect. Therefore, CRP can be useful for the diagnosis and determination of progression of periodontal disease (PD). The aim of this study was to assess CRP levels in patients with PD and patients with PD and type 2 diabetes (T2D). 60 subjects were included and divided into 3 groups: 15 patients with PD (Group 1), 15 patients with PD and T2D (group 2) and 30 patients systemically healthy (group 3). Each participant underwent biochemical tests: Protein C Reactive (NycoCard® CPR), HbA1c (NycoCard®) and blood glucose test. Weight, height, body mass index (BMI) and periodontal loss of attachment were registered. For diagnosis of periodontal disease, we followed the parameters of the 5th European Workshop on Periodontology. Kruskal Wallis test was used to evaluate the differences between the groups. Significant statistical differences were found when comparing the CRP concentration in the 3 groups (p<0.01), finding that the healthy group showed the lowest mean (4.88±0.08) and the highest mean values were shown in the PE groups (5.95±2.23) and EP/T2D (5.21±0.20). Also, significant differences (p<0.01) were found in the three groups, in relation to hemoglobin concentration, height, body mass index and periodontal loss of attachment. The results indicate that serum levels of CRP rise in patients with PD and in patients with PE and T2D. Although this difference was noted, there are several local and systemic factors that can potentially influence CRP levels and these represent a limitation and difficulty when interpreting the tests.

Resumen La Proteína C Reactiva (PCR) es una de las proteínas plasmáticas que aparecen en la fase aguda de la inflamación. La periodontitis se relaciona con niveles elevados de PCR en adultos y con una reducción de la misma después de su tratamiento. La diabetes, por otro lado, es una enfermedad que compromete la respuesta tanto inflamatoria como reparativa del organismo y los tejidos periodontales son particularmente sensibles a su efecto. La PCR por lo tanto, puede ser útil en el diagnóstico y en la determinación de progresión de la enfermedad periodontal (EP). El objetivo del presente estudio fue evaluar los niveles de PCR en pacientes con EP y pacientes con EP y diabetes mellitus tipo 2 (DM2). Se incluyeron 60 sujetos distribuidos en 3 grupos: 15 pacientes con EP (Grupo 1), 15 pacientes con EP y DM2 (grupo 2) y 30 pacientes sistémicamente sanos (grupo 3). A cada uno de los participantes se les realizaron pruebas bioquímicas: Proteína C Reactiva (NycoCard® PCR), HbA1c (NycoCard®) y glucosa en sangre. Para el diagnóstico de la enfermedad periodontal se siguieron los parámetros del 5° Taller Europeo de Periodontología. Para evaluar las diferencias entre los grupos se usó la prueba de Kruskal Wallis. Se encontraron diferencias estadísticas significativas al comparar la concentración de PCR en los 3 grupos (p<0.01), siendo el grupo de pacientes sanos el que presentaba el menor promedio (4.88±0.08) y los mayores promedios para los grupos de EP (5.95±2.23) y EP/DM2 (5.21±0.20). Además se encontraron diferencias significativas (p<0.01) en los tres grupos con respecto a la concentración hemoglobina, talla, IMC y PI. Los resultados indican que los niveles séricos de PCR se elevan en pacientes con EP y en pacientes con EP y DM2. Aunque se notó esta diferencia, existen diversos factores tanto locales como sistémicos que pueden potencialmente influir en los niveles de PCR y estos representan una limitación y dificultad al momento de interpretar las pruebas.

AbstractBackground The American trypanosomiasis is a zoonosis caused by the protozoaTrypanosoma cruzi (T. cruzi). The disease is widely distributed throughout the American continent, affecting a wide range of hosts, including dogs. It is present in the canine population in the State of Yucatan, Mexico. However, no significant studies in owned dogs have been performed in the metropolitan area of Merida. A transversal study was conducted in 370 owned dogs from Merida, Yucatan, Mexico.Methods A cross-sectional study including 370 dogs was performed in a major city of Yucatan, Mexico, to detect IgG antibodies against T. cruzi. A commercial ELISA test kit was used and a chi-square test used to evaluate associated risk factors; odds ratio (OR) and 95 % confidence interval (CI) were also estimated.Results The indirect ELISA and western blot (WB) tests were used to detect specific immunoglobulin G antibodies against T. cruzi in serum samples. A prevalence of 12.2 % was found; age and area of residence were statistically associated with seropositivity in dogs (p<0.05).Conclusions Results from the present study suggests the presence and abundance of the vector in urban conditions where a high number of seropositive cases ofT. cruzi cases were found.